Clinical Trial Update: Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC [Phase 1, Phase 2]

View source ↗

Summary

A first-line trial evaluating lenvatinib in combination with camrelizumab for advanced hepatocellular carcinoma is in Phase 1/2 with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN